##common.pageHeaderLogo.altText##

Review article: Medical guidelines

Vol. 155 No. 8 (2025)

Swiss recommendations on driving ability in patients with diabetes mellitus

Cite this as:
Swiss Med Wkly. 2025;155:4665
Published
14.08.2025

Summary

Most people with diabetes mellitus operate motor vehicles safely without creating any meaningful risk on the road for themselves or others. A diagnosis of diabetes is, in itself, inadequate for determining a person’s driving capability or safety. Diabetes-related traffic accidents are rare for most drivers with diabetes mellitus and occur less frequently than for many other diseases that can impair driving performance and that are tolerated by society. The incidence of hypoglycaemia, which impairs the ability to drive, severe retinopathy (including macular oedema) or cataract formation affecting visual acuity required to drive a motor vehicle, and peripheral neuropathy, which can severely impair sensation in the feet, is not so common as to justify restricting driving privileges for all drivers with diabetes mellitus.

In recent years, several pharmacological and technological innovations have revolutionised diabetes care. Continuous glucose monitoring system (CGMS) technology has only recently become increasingly integrated into diabetes therapy. Today, except for insulin, none of the treatments recommended for type 2 diabetes mellitus causes hypoglycaemia, and the risk of hypoglycaemia with ultra-long-acting insulins is lower. As a result, recommendations for driving motor vehicles have had to be adjusted. Since hypoglycaemia is the greatest risk factor for impaired driving ability, the latest technology (CGMS coupled with hybrid closed-loop insulin pumps) can reduce the number of hypoglycaemic events and blood glucose fluctuations. In addition, HbA1c and time in target range can be improved. Patients with type 1 diabetes mellitus are now, in exceptional cases, allowed to be licensed in higher vehicle categories. With the analysis of CGMS data, an objective assessment of the frequency of hypoglycaemia is now possible; this was previously only partially possible with blood glucose logs. Patients who are treated with insulin should use a CGMS. This also applies to gestational diabetes and diabetes during pregnancy. Since these systems warn of impending hypoglycaemia, they will also improve road safety, and the safety margin for blood glucose, previously set at 5 mmol/l, can be lowered to 4 mmol/l. For CGMS users, blood glucose measurements every 2 hours while driving are no longer necessary.

References

  1. Graveling AJ, Warren RE, Frier BM. Hypoglycaemia and driving in people with insulin-treated diabetes: adherence to recommendations for avoidance. Diabet Med. 2004 Sep;21(9):1014–9. doi: https://doi.org/10.1111/j.1464-5491.2004.01288.x
  2. Inkster B, Frier BM. Diabetes and driving. Diabetes Obes Metab. 2013 Sep;15(9):775–83. doi: https://doi.org/10.1111/dom.12071
  3. Kagan AH, Hashemi G, Korner-Bitensky N. Diabetes Fitness to Drive: A Systematic Review of the Evidence with a Focus on Older Drivers. Can J Diabetes. 2010;34(3):233–42. doi: https://doi.org/10.1016/S1499-2671(10)43012-9
  4. Hostiuc S, Negoi I, Hostiuc M. Diabetes and collision risk. A meta-analysis and meta-regression. Int J Clin Pract. 2016 Jul;70(7):554–68. doi: https://doi.org/10.1111/ijcp.12832
  5. Cox DJ, Penberthy JK, Zrebiec J, Weinger K, Aikens JE, Frier B, et al. Diabetes and driving mishaps: frequency and correlations from a multinational survey. Diabetes Care. 2003 Aug;26(8):2329–34. doi: https://doi.org/10.2337/diacare.26.8.2329
  6. Stork AD, van Haeften TW, Veneman TF. Diabetes and driving: desired data, research methods and their pitfalls, current knowledge, and future research. Diabetes Care. 2006 Aug;29(8):1942–9. doi: https://doi.org/10.2337/dc05-2232
  7. Rayman G, Kröger J, Bolinder J. Could FreeStyle Libre™ sensor glucose data support decisions for safe driving? Diabet Med. 2018 Apr;35(4):491–4. doi: https://doi.org/10.1111/dme.13515
  8. Gastaldi G, Lucchini B, Thalmann S, Alder S, Laimer M, Brändle M, et al.; Working group of the SGED/SSED. Swiss recommendations of the Society for Endocrinology and Diabetes (SGED/SSED) for the treatment of type 2 diabetes mellitus (2023). Swiss Med Wkly. 2023 Apr;153(4):40060. doi: https://doi.org/10.57187/smw.2023.40060
  9. Lehmann V, Zueger T, Maritsch M, Kraus M, Albrecht C, Bérubé C, et al. Machine learning for non-invasive sensing of hypoglycaemia while driving in people with diabetes. Diabetes Obes Metab. 2023 Jun;25(6):1668–76. doi: https://doi.org/10.1111/dom.15021
  10. Lehmann V, Zueger T, Maritsch M, Notter M, Schallmoser S, Bérubé C, et al. Machine learning to infer a health state using biomedical signals – detection of hypoglycemia in people with diabetes while driving real cars. NEJM AI. 2024 Jan;1(3): 10.1056/AIoa2300013
  11. Diabetes UK. Know Diabetes. Fight Diabetes. Driving and diabetes – What healthcare professionals should know. Available from: https://www.diabetes.org.uk/for-professionals/get-involved/news-and-updates/driving-and-diabetes--what-healthcare-professionals-should-know
  12. Orchard TJ, Dorman JS, Maser RE, Becker DJ, Drash AL, Ellis D, et al. Prevalence of complications in IDDM by sex and duration. Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes. 1990 Sep;39(9):1116–24. doi: https://doi.org/10.2337/diab.39.9.1116
  13. Hatz K, Minder AE, Lehmann R, Drescher T, Gerendas B, Schmidt-Erfurth U, et al. The prevalence of retinopathy in patients with type 1 diabetes treated with education-based intensified insulin therapy and its association with parameters of glucose control. Diabetes Res Clin Pract. 2019 Feb;148:234–9. doi: https://doi.org/10.1016/j.diabres.2019.01.016
  14. Lehmann R, Troendle A, Brändle M; Schweizerischen Gesellschaft für Endokrinologie und Diabetologie. [New insights into diagnosis and management of gestational diabetes mellitus: recommendations of the Swiss Society for Endocrinology and Diabetes]. Ther Umsch. 2009 Oct;66(10):695–706. doi: https://doi.org/10.1024/0040-5930.66.10.695
  15. Sweeting A, Wong J, Murphy HR, Ross GP. A Clinical Update on Gestational Diabetes Mellitus. Endocr Rev. 2022 Sep;43(5):763–93. doi: https://doi.org/10.1210/endrev/bnac003
  16. Group HS; HAPO Study Cooperative Research Group. Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study: associations with neonatal anthropometrics. Diabetes. 2009 Feb;58(2):453–9. doi: https://doi.org/10.2337/db08-1112
  17. Nielsen LR, Pedersen-Bjergaard U, Thorsteinsson B, Johansen M, Damm P, Mathiesen ER. Hypoglycemia in pregnant women with type 1 diabetes: predictors and role of metabolic control. Diabetes Care. 2008 Jan;31(1):9–14. doi: https://doi.org/10.2337/dc07-1066
  18. Grasso S, Palumbo G, Rugolo S, Cianci A, Tumino G, Reitano G. Human fetal insulin secretion in response to maternal glucose and leucine administration. Pediatr Res. 1980 May;14(5):782–3. doi: https://doi.org/10.1203/00006450-198005000-00016
  19. Obenshain SS, Adam PA, King KC, Teramo K, Raivio KO, Räihä N, et al. Human fetal insulin response to sustained maternal hyperglycemia. N Engl J Med. 1970 Sep;283(11):566–70. doi: https://doi.org/10.1056/NEJM197009102831104
  20. Jovanovic L. Medical nutritional therapy in pregnant women with pregestational diabetes mellitus. J Matern Fetal Med. 2000;9(1):21–8. doi: https://doi.org/10.1002/(SICI)1520-6661(200001/02)9:1<21::AID-MFM6>3.0.CO;2-P
  21. Kowalski A. Pathway to artificial pancreas systems revisited: moving downstream. Diabetes Care. 2015 Jun;38(6):1036–43. doi: https://doi.org/10.2337/dc15-0364
  22. Lehmann R. Technologie bei der Behandlung des Diabetes mellitus Typ 1: ersetzt das künstliche Pankreas das traditionelle Basis-Bolus-System? Diabetes Stoffwechs Herz. 2019;28(2):98–101.
  23. Snell-Bergeon JK, Wadwa RP. Hypoglycemia, diabetes, and cardiovascular disease. Diabetes Technol Ther. 2012;14 Suppl 1(Suppl 1):S51-8. doi: https://doi.org/10.1089/dia.2012.0031